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been quantiﬁed adopting the perspective of the third party payer,
i.e. the National Health Service. To determine cost-effectiveness,
we calculated the incremental cost-effectiveness ratio (ICER) as
the ratio of the difference in costs between ODP and PP to the
difference in number-of-bleedings. The nonparametric bootstrap
procedure was employed to generate Conﬁdence Intervals (CIs).
A cost-effectiveness plane and an acceptability curve were
created. The cost-effectiveness acceptability curve represents the
probability that Prophylactic treatment with Refacto® is cost-
effective at all possible values of the maximum acceptable CER
appropriate for decision-making. RESULTS: Nineteen patients,
aged 23–58 years (mean = 33.2) with a mean of 2.97
events/patient/month (median = 1.67, range: 0.5–15) were
enrolled. The incremental-costs of PT versus ODT was estimated
to be €11,619/month (95%CI €7649–15,589) with an additional
effect of 2.49 bleeding-avoided/month (1.06–3.93). The cost-
effectiveness was estimated to be €5184 per bleeding avoided
(€1071–9297). If the ceiling CER is €4500 per bleeding-avoided,
there is a 50% chance that PT is cost-effective. The likelihood
of PT being cost-effective increases to 95% with a ceiling ratio
of €9000/bleeding-avoided. CONCLUSIONS: These ﬁndings
showed prophylaxis with Refacto® in adults with haemophilia
was effective. Our cost-effectiveness results can represent the
point of reference for other similar evaluations.
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OBJECTIVE: To examine characteristics, length of stay (LOS),
and costs associated with trauma-related hospital admissions
with and without blood transfusions. METHODS: The 2003
Health care Cost and Utilization Project database was used to
examine short-stay acute-care hospital discharges for trauma
among adults with and without transfusions. This dataset
includes all discharges from 995 hospitals in 35 states in the U.S.
Trauma discharges were identiﬁed using ICD-9-CM diagnosis
and E-codes; evidence of transfusion was inferred from proce-
dure codes. Patient-level information included demographics,
hospital characteristics, comorbidities, primary payer, admission
source, discharge destination, estimated loss of function (ELOF),
LOS, and hospital charges. Costs were estimated by applying
hospital-speciﬁc cost-to-charge ratios to charges. Determinants
of LOS and cost were assessed through multivariate least-squares
regression. LOS and costs were log-transformed prior to the mul-
tivariate analyses and retransformation following estimation was
undertaken employing the smearing method developed by Duan
and colleagues. RESULTS: Of the 263,816 trauma-related dis-
charges in 2003, 28,859 (11%) had evidence of blood transfu-
sion. Patients with transfusion were more likely than those
without transfusion to be female (68% vs. 52% without hem-
orrhage), aged 65+ years (78% vs. 47%), major or extreme
ELOF (46% vs. 19%), and to die in hospital (6% vs. 2%). After
adjusting for covariates and retransformation, patients with
transfusion, on average, stayed 1.8 more days and cost an addi-
tional $5400 (both p < 0.01). Signiﬁcant predictors (all p < 0.01)
of increased cost included male gender; Hispanic and Asian 
(vs. white) race; care at large, urban, and teaching hospitals; 
coverage by private (vs. public) payer, admission through the
emergency room, increased ELOF, and in-hospital mortality. 
Predictors of decreased cost included older age, black (vs. white)
race, and Midwest region (vs. Northeast). CONCLUSION:
Trauma patients with transfusion account for a disproportion-
ate share of inpatient trauma-related resource use and cost.
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OBJECTIVES: To estimate the incremental hospital costs 
and related length of stay associated with the development of
thrombocytopenia in a general medical/surgical population.
METHODS: We included patients from the Complications After
Thrombocytopenia Caused by Heparin (CATCH) Registry
treated with heparin for ≥96 hours (n = 1997). Hospital costs
for all CATCH patients were estimated using hospital cost
accounting system results for CATCH Registry patients enrolled
at Duke University Medical Center (n = 336). After adjusting 
for baseline characteristics, and procedures and complications
occurring before 96 hours, we estimated incremental hospital
costs associated with thrombocytopenia deﬁned prospectively by
a platelet count drop to <150 × 103/mm3, a platelet count reduc-
tion >50% from admission level, or both. RESULTS: Overall,
28% of CATCH patients receiving heparin for ≥96 hours devel-
oped thrombocytopenia. These patients more commonly had a
history of MI (23% vs. 15%), heart failure (29% vs. 24%), and
experienced more in-hospital death (5.1% vs. 1.1%) than
patients who did not develop thrombocytopenia. The total pop-
ulation’s average length of stay was 14.5 days with mean hospi-
tal costs of $29,523, but both values were signiﬁcantly greater
among patients developing thrombocytopenia (18.0 vs. 13.2
days, and $45,192 vs. $23,527). After adjustment, the develop-
ment of thrombocytopenia in all groups remained a signiﬁcant
marker for increased hospital costs over patients without throm-
bocytopenia (incremental costs = $5262 in patients with a
platelet count drop to <150 × 103/mm3, $9340 in patients with
a platelet count reduction >50% from admission level, and
$18,488 in patients meeting both criteria). CONCLUSIONS:
The incremental economic impact of thrombocytopenia, experi-
enced commonly among hospitalized patients, is substantial.
Strategies that minimize or effectively prevent the development
of thrombocytopenia may therefore be economically attractive.
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OBJECTIVES: Cancer patients receiving chemotherapy com-
monly experience hematologic adverse events (AEs) which
increase the costs of care. This study examined the economic out-
comes of neutropenia, thrombocytopenia, and anemia as AEs of
chemotherapy treatment. METHODS: A systematic search of
the medical literature (1990–2006) was conducted for each AE
using costs/economics as search terms. Additional searches were
conducted from article bibliographies and conference proceed-
ings (2000–2006). Articles selected were prospective or retro-
spective studies speciﬁcally designed to examine burden of
illness, direct medical costs, or cost drivers associated with hema-
tologic AEs in adult cancer patients undergoing chemotherapy.
